Earnings summaries and quarterly performance for Centessa Pharmaceuticals.
Executive leadership at Centessa Pharmaceuticals.
Saurabh Saha
Detailed
Chief Executive Officer
CEO
Gregory Weinhoff
Detailed
Chief Business Officer
Iqbal Hussain
Detailed
General Counsel
John Crowley
Detailed
Chief Financial Officer
Karen Anderson
Detailed
Chief People Officer
Raphael Deferiere
Detailed
Chief Accounting Officer
Steven Kanes
Detailed
Chief Medical Officer
Tia Bush
Detailed
Chief Technology and Quality Officer
Board of directors at Centessa Pharmaceuticals.
Research analysts covering Centessa Pharmaceuticals.
Recent press releases and 8-K filings for CNTA.
Centessa Pharmaceuticals Provides Update on Orexin Agonist Programs and Phase 2 ORX750 Study
CNTA
Product Launch
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals highlighted its focus on orexin biology, with its lead asset ORX750 demonstrating clinically meaningful and statistically significant efficacy in initial Phase 2 cohorts for narcolepsy type 1, type 2, and idiopathic hypersomnia.
- The Phase 2 data for ORX750 showed a potential best-in-class profile with no adverse events limiting the therapeutic index, and only three cases of non-clinically meaningful, mild, and transient visual disturbances reported across 55 patients.
- The company is expanding its orexin agonist franchise with ORX142 and ORX489, both scheduled to enter Phase 1 studies in Q1 2026 for broader indications such as neurodegenerative and psychiatric disorders.
- Centessa anticipates providing a further update on the Phase 2 study and initiating its registrational program in Q1 2026.
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Future Orexin Program Milestones
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported clinically meaningful and statistically significant efficacy from initial cohorts of its ORX750 Phase 2 study in narcolepsy type 1, type 2, and idiopathic hypersomnia, indicating a potential best-in-class profile.
- Key efficacy results for ORX750 included a greater than 20-minute change from baseline on MWT for narcolepsy type 1 and a greater than 10-minute change from baseline on MWT (placebo adjusted) for narcolepsy type 2.
- Safety data across 55 patients for ORX750 showed only three mild, transient, non-clinically meaningful visual disturbances with no dose response.
- Centessa is advancing its orexin agonist franchise with ORX142 and ORX489, both scheduled to enter Phase 1 studies in Q1 2026 for broader indications such as neurodegenerative and psychiatric disorders.
- The company anticipates providing a further Phase 2 data update and initiating its registrational program for ORX750 in Q1 2026.
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Provides Update on Orexin Agonist Pipeline and ORX750 Phase II Data
CNTA
New Projects/Investments
Guidance Update
Dec 3, 2025, 2:35 PM
Centessa Pharmaceuticals Updates on Orexin Program and Clinical Development Timelines
CNTA
New Projects/Investments
Guidance Update
Product Launch
- Centessa Pharmaceuticals provided an update on its ORX750 Phase 2 study, demonstrating statistically significant and clinically meaningful efficacy across Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia (IH).
- In NT1, ORX750 showed a greater than 20-minute change from baseline in MWT and reduced ESS from 19 to 5, with cataplexy suppression to a 0.13 incidence rate ratio.
- For NT2, ORX750 achieved a greater than 10-minute change from baseline in MWT and reduced ESS from 15-16 to 8.
- The company plans to initiate the registration program (Phase 3) for ORX750 in Q1 2026 and will provide a further update on the next 50 patients in Q1 2026.
- Centessa is also advancing ORX142 into patient studies and ORX489 into Phase 1 studies, both in Q1 2026, aiming to expand beyond rare hypersomnias into broader neurodegenerative and psychiatric conditions.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Updates on Orexin Program and Future Milestones
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals provided an update on its ORX750 Phase II study, highlighting robust and statistically significant efficacy across narcolepsy type 1, type 2, and idiopathic hypersomnia, suggesting a potential best-in-class profile.
- The company plans to provide a further update on ORX750 data and commence its registrational program (Phase III) in Q1 2026.
- Centessa's pipeline includes additional orexin agonists, ORX142 and ORX489, both entering Phase I studies in Q1 2026, with the potential to address broader neurodegenerative and psychiatric conditions.
- The Orexin program is supported by homegrown intellectual property (IP), with protection extending past 2040.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Updates on Orexin Program Progress
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported robust Phase 2 data for its orexin agonist ORX750 across Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia (IH), demonstrating clinically and statistically significant efficacy.
- For NT1, ORX750 achieved a greater than 20-minute change from baseline in MWT and reduced ESS from 19 to 5; for NT2, it showed a greater than 10-minute change from baseline in MWT and reduced ESS from 15-16 to 8.
- The company plans to initiate the registration program (Phase 3) for ORX750 in Q1 2026, with an update on additional Phase 2 data expected in the same quarter.
- Centessa's pipeline includes ORX142 and ORX489, both entering Phase 1 studies in Q1 2026, aiming to expand beyond rare hypersomnias into neurodegenerative and psychiatric conditions.
- The company holds homegrown intellectual property for its small molecules, with protection extending past 2040.
Dec 2, 2025, 8:00 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Future Plans
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported positive Phase 2 data for ORX750 across narcolepsy type 1 (NT1), type 2 (NT2), and idiopathic hypersomnia (IH), demonstrating clinically and statistically significant efficacy and a potential best-in-class profile.
- ORX750 exhibited a clean safety profile with only three cases of transient and mild visual disturbances across 50 patients, and a pharmacokinetic profile supporting once-daily (QD) dosing with rapid onset and extended coverage.
- The company plans to start a registration program in Q1 2026 for ORX750, potentially across all three indications, and is continuing dose escalation in the ongoing Phase 2 study.
- Centessa estimates the market opportunity for NT1, NT2, and IH at approximately $18 billion and reported a proforma balance sheet of $620 million.
Nov 18, 2025, 2:00 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Future Plans
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals' ORX750 Phase 2 study demonstrated clinically and statistically significant efficacy across narcolepsy type 1, type 2, and idiopathic hypersomnia, showing a potential best-in-class profile in NT1 and NT2.
- The drug exhibited a highly tolerable safety profile, with only three cases of transient and mild visual disturbances reported across 50 patients, which were non-clinically meaningful, transient, and mild.
- The company plans to initiate a registration program for ORX750 in Q1 2026 and continues dose escalation with over 50 patients.
- Centessa estimates the market opportunity for orexin agonists in these indications to be $18 billion, with a proforma cash balance of $620 million.
Nov 18, 2025, 2:00 PM
Centessa Pharmaceuticals Reports Positive ORX750 Phase 2 Data and Outlines Q1 2026 Clinical Milestones
CNTA
New Projects/Investments
Guidance Update
- Centessa Pharmaceuticals reported positive Phase 2 data for its orexin agonist, ORX750, demonstrating clinically and statistically significant efficacy across narcolepsy type 1 (NT1), type 2 (NT2), and idiopathic hypersomnia (IH).
- The ORX750 data showed strong efficacy in NT1 (e.g., >20 minute MWT change from baseline at 1.5 mg QD) and NT2 (>10 minute MWT change from baseline at 4 mg), coupled with a highly tolerable safety profile with only three cases of transient, mild visual disturbances across 50 patients.
- The company plans to start the registration program for ORX750 in Q1 2026 and is advancing its broader orexin agonist pipeline, with ORX142 and ORX489 also entering clinical studies in Q1 2026.
- Centessa estimates the market opportunity for NT1, NT2, and IH to be $18 billion and reported a proforma cash balance of $620 million.
Nov 18, 2025, 2:00 PM
Centessa Pharmaceuticals plc Prices Public Offering of American Depositary Shares
CNTA
- Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (ADSs) at $21.50 per ADS on November 11, 2025.
- The offering is expected to generate approximately $250 million in aggregate gross proceeds for the company.
- Centessa has granted the underwriters a 30-day option to purchase up to an additional 1,744,186 ADSs.
- The estimated net proceeds of approximately $234.4 million (or $269.6 million if the over-allotment option is fully exercised) will be used to fund product candidate development and for general corporate purposes.
- The offering is expected to close on or about November 14, 2025.
Nov 13, 2025, 12:24 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more